[1]鲁胜男,冯彦林.乳腺癌新辅助化疗过程中18F-FDG PET-CT与化疗前Ki-67、COX-2表达的相关性研究[J].国际放射医学核医学杂志,2011,35(4):238-240.[doi:10.3760/cma.j.issn.1673-4114.2011.04.011]
 LU Sheng-nan,FENG Yan-lin.The correlation analysis between 18F-FDG PET-CT in breast cancer with neoadjuvant chemotherapy and the expression of Ki-67 and COX-2 before neoadjuvant chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):238-240.[doi:10.3760/cma.j.issn.1673-4114.2011.04.011]
点击复制

乳腺癌新辅助化疗过程中18F-FDG PET-CT与化疗前Ki-67、COX-2表达的相关性研究(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
35
期数:
2011年第4期
页码:
238-240
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
The correlation analysis between 18F-FDG PET-CT in breast cancer with neoadjuvant chemotherapy and the expression of Ki-67 and COX-2 before neoadjuvant chemotherapy
作者:
鲁胜男 冯彦林
中山大学附属佛山市第一人民医院核医学科, 佛山 528000
Author(s):
LU Sheng-nan FENG Yan-lin
Department of Nuclear Medicine, Affiliated Foshan Hospital of Sun Yat-sen University, Foshan 528000, China
关键词:
乳腺肿瘤化学疗法辅助Ki-67抗原环氧合酶2正电子发射断层显像术体层摄影术X线计算机
Keywords:
Breast neoplasmsChemotherapyadjuvantKi-67 antigenCycloocygenase 2Positron-emission tomographyTomographyX-ray computed
DOI:
10.3760/cma.j.issn.1673-4114.2011.04.011
摘要:
目的 研究乳腺癌新辅助化疗过程中18F-FDG PET-CT的病灶最大标准化摄取值(SUVmax)的变化与其化疗前Ki-67(一种增殖细胞核抗原)、环氧合酶2(COX-2)表达的相关性。方法 初治乳腺癌患者19例,在新辅助化疗前、第1疗程结束后及第2疗程结束后分别行18F-FDG PET-CT,并计算病灶的SUVmax变化率,在新辅助化疗前取患者乳腺肿瘤组织标本进行Ki-67、COX-2免疫组化检查,并比较不同Ki-67和COX-2表达组之间的SUVmax变化率。结果 新辅助化疗前、第1疗程及第2疗程结束后的SUVmax变化率在化疗前Ki-67、COX-2不同表达组之间差异均无统计学意义。结论 化疗前Ki-67、COX-2的表达情况无法充分解释病灶在新辅助化疗过程中18F-FDG的摄取变化,而其最有可能的解释是细胞之间复杂的能源需求与肿瘤微环境的相互作用。
Abstract:
Objective To study the expression of Ki-67(a kind of proliferation cell nuclear antigen), cyclooxygenase-2(COX-2) in breast cancer before neoadjuvant chemotherapy, and its correlation with the changes of maximum standarded uptake value(SUVmax). Methods In a prospertive trial, 18F-FDG PET-CT were performed in 19 women with primary breast cancer before and after the first and second cycle of neoadjuvant chemotherapy respectively, the changes of SUVmax were computered. Divided the patients into different groups according to the Ki-67 and COX-2 expression, then compared the rate of change of SUVmax in different groups. Results There was no correlation between the changes of SUVmax after chemotherapy and the expression of Ki-67, COX-2 before neoadjuvant chemotherapy. Conclusions The expression of Ki-67 and COX-2 before neoadjuvant chemotherapy were unable to sufficiently explain the changes of 18F-FDG uptake during the chemotherapy process. The metabolic changes were most likely explained by a complex interaction between cellular energy demand and tumoral microenvironment.

参考文献/References:

[1] Chang JC,Wooten EC,Tsimelzon A,et al.Gene expression profiling for the prediction of therapeutic response to docetaxel inpatients with breast cancer.Lancet,2003,362(9381):362-369.
[2] 林其声,施雄文,徐书楷,等.新辅助化疗对乳腺癌ki-67、cox-2,p53表达的影响及其临床意义.中国当代医药,2009,16(24):13-14.
[3] McDermott GM,Welch A,Staff RT,et al.Monitoring primary breast cancer throughout chemotherapy using FDG-PET.Breast Cancer Res Treat,2007,102(1):75-84.
[4] Schwarz-Dose J,Untch M,Tiling R,et al.Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose.J Clin Oncol,2009,27(4):535-541.
[5] 温广华,冯彦林,黄克敏,等.乳腺癌18F-FDG PET/CT标准化摄取值与Ki-67表达关系的初步研究.中国临床医学影像杂志,2010,21(7):509-511.
[6] 何仲琴,李恩孝.环氧化酶-2表达与肿瘤关系的研究进展.现代肿瘤医学,2005,13(4):573-575.
[7] Ruibal A,Abdulkader I,Gude F,et al.The immunohistochemical expression of cyclooxygenase 2 is inversely associated with 18F-FDG-PET SUV values in non-small-cell lung cancers.Initial results.Rev Esp Med Nucl,2009,28(1):11-14,
[8] Surowiak P,Materna V,Matkowski R,et al.Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance,Breast Cancer Res,2005,7(5):R862-R870.
[9] Denkert C,Winzer KJ,Hauptmann S.Prognostic impact of cyclooxygenase-2 in breast cancer.Clin Breast Cancer,2004,4(6):428-433.
[10] Zhao X,Goswami M,Pokhriyal N,et al.Cyclooxygenase-2 expression during immortalization and breast cancer progression.Cancer Res,2008,68(2):467-475.

相似文献/References:

[1]杨雷,袁卫红,王家平,等.99Tcm-MIBI显像与钼靶X线对乳腺癌诊断的比较研究[J].国际放射医学核医学杂志,2016,40(2):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
 Yang Lei,Yuan Weihong,Wang Jiaping,et al.Diagnostic value of technetium 99Tcm sestamibi and X-ray mammography in breast cancer: a comparison study[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
[2]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
 Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[3]储小飞,赵舒怡,樊赛军.肿瘤干细胞与辐射抗性的研究进展[J].国际放射医学核医学杂志,2015,39(5):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
 chu xiaofei,zhao shuyi,fan saijun..advance progress of cancer stem cells and radioresistance[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
[4]陈伟君,孙达.99Tcm-MIBI显像在乳腺癌新辅助化疗中的应用价值[J].国际放射医学核医学杂志,2015,39(6):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
 Chen Weijun,Sun Da.Clinical value of 99Tcm-MIBI imaging in neoadjuvant chemotherapy of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
[5]胡鸿,唐刚华,聂大红.乳腺癌分子显像研究进展[J].国际放射医学核医学杂志,2015,39(1):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
 Hu Hong,Tang Ganghua,Nie Dahong.Progress on molecular imaging of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
[6]黄娟,颜剑豪,梁联保,等.注射钆剂后弥散加权成像对乳腺肿瘤诊断的影响[J].国际放射医学核医学杂志,2015,39(4):287.[doi:10.3760/cma.j.issn.1673-4114.2015.04.003]
 Huang Juan,Yan Jianhao,Liang Lianbao,et al.Evaluation of the diffusion-weighted imaging after contrast for the characterization of breast tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):287.[doi:10.3760/cma.j.issn.1673-4114.2015.04.003]
[7]查金顺,蒋艳,徐源,等.131I辅以短期小剂量碳酸锂治疗Graves甲亢的研究[J].国际放射医学核医学杂志,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
 Zha Jinshun,Jiang Yah,Xu Yuan,et al.Clinical research on radioiodine addition of low-doses of lithium carbonate in short-term treatment of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
[8]李雯,冯彦林.18F-FDG PET/CT评估三阴性乳腺癌新辅助化疗疗效的研究进展[J].国际放射医学核医学杂志,2014,38(3):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
 Li Wen,Feng Yanlin.Advances of assessment with 18F-FDG PET/CT in triple-negative breast cancer during neoadjuvant chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
[9]殷丽娜,张旭霞,张俊香,等.Wnt/β-catenin信号通路——乳腺癌的潜在治疗靶点[J].国际放射医学核医学杂志,2014,38(4):252.[doi:10.3760/cma.j.issn.1673-4114.2014.04.011]
 Yin Lina,Zhang Xuxia,Zhang Junxiang,et al.The Wnt/β-catenin signaling pathway-a potential therapeutic target of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):252.[doi:10.3760/cma.j.issn.1673-4114.2014.04.011]
[10]刘超,邓智勇,刘鹏杰,等.89SrCL2与唑来膦酸联合治疗乳腺癌转移性骨肿瘤的疗效分析[J].国际放射医学核医学杂志,2014,38(5):300.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
 Liu Chao,Deng Zhi-yong,Liu Peng-jie,et al.Analysis on the curative effect of combination therapy with zoledronic acid and 89SrCL2 on bone tumor with breast cancer metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):300.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
[11]贾莉,邓智勇.乳腺癌新辅助化疗疗效评价的相关研究[J].国际放射医学核医学杂志,2013,37(4):239.[doi:10.3760/cma.j.issn.1673-4114.2013.04.012]
 JIA Li,DENG Zhi-yong.Evaluation of response to neoadjuvant chemotherapy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):239.[doi:10.3760/cma.j.issn.1673-4114.2013.04.012]

备注/Memo

备注/Memo:
收稿日期:2011-05-03。
通讯作者:冯彦林(Email:lsn302208@tom.com)
更新日期/Last Update: 1900-01-01